| Ytd | 3.19% | |
| 1y | 118.57% |
| Open | 5.28 | Prev Close | 5.39 | Low | 5.15 | High | 5.37 | Mkt Cap | 644.62M |
| Vol | 688.74K | Avg Vol | 3.48M | EPS | -1.22 | P/E | -4.42 | Forward P/E | -6.48 |
| Beta | 1.16 | Short Ratio | 6.15 | Inst. Own | 92.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 5.39 | 200-d Avg | 5.05 | 1yr Est | 13.71 |
ANNX News
Citizens analyst Jonathan Wolleben initiates coverage on Annexon (NASDAQ:ANNX) with a Market Unde
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutica
Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price t
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutica
Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably
BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutica
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcr
Annexon NASDAQ: ANNX executives used a Goldman Sachs Healthcare Conference session to outline the co
Annexon NASDAQ: ANNX executives outlined a series of expected clinical and regulatory updates across
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical
BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical
Annexon NASDAQ: ANNX President and CEO Doug Love outlined the company's late-stage pipeline and regu
Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Goldman Sachs analyst Salveen Richter initiates coverage on Annexon (NASDAQ:ANNX) with a Neutral
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year ma
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.23) per share which beat the analyst consensu
Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical
Annexon (NASDAQ: ANNX) President and CEO Doug Love outlined a series of anticipated clinical and reg
Shares of Annexon, Inc. (NASDAQ: ANNX - Get Free Report) traded down 6.1% on Friday. The company tra
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutic
The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which beat the analyst consensu
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has
BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutic
On Monday, 147 stocks hit new 52-week lows.
On Thursday, 147 companies achieved new lows for the year.